Molecular characterization of β-thalassemia intermedia in the West Bank, Palestine.

Q2 Medicine
Rashail Faraon, Mahmoud Daraghmah, Fekri Samarah, Mahmoud A Srour
{"title":"Molecular characterization of β-thalassemia intermedia in the West Bank, Palestine.","authors":"Rashail Faraon,&nbsp;Mahmoud Daraghmah,&nbsp;Fekri Samarah,&nbsp;Mahmoud A Srour","doi":"10.1186/s12878-019-0135-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to investigate the molecular basis of β-Thalassemia intermedia (TI) in the West Bank region and its management practices.</p><p><strong>Methods: </strong>This was a case series multi-center study and included 51 cases of TI. DNA sequencing was used to analyze β-globin gene mutations. Common α-globin gene mutations were screened by Gap-PCR (-α<sup>3.7</sup>, -α<sup>4.2</sup>, --<sup>MED</sup>, ααα<sup>anti3.7</sup>) or DNA sequencing (α2-IVS II 5 nt del). <i>Xmn</i>I -158 C > T polymorphisms of Gγ-globin gene was determined by RFLP-PCR.</p><p><strong>Results: </strong>Seven β-globin gene mutations were observed, namely IVS-I -6 C > T, IVS-I-110 G > A, IVS-II-1 G > A, IVS-I-1 G > A, Codon 37 Trp > Stop, beta - 101 and IVS-II-848 C > A. Ten genotypes were observed. Homozygosity for IVS-I-6 accounted for the majority of TI cases with a frequency of 74.5%. The second common β-globin gene genotype was homozygote IVS-I-110 G > A (5.8%) and homozygote IVS-II-1 G > A (5.8%). The remaining seven genotypes were each detected in about 2% of patients. α-Thalassemia mutations were seen in five patients (9.8%), and included (-α<sup>3.7</sup>, ααα<sup>anti3.7</sup> and α2-IVSII-5 nt del). <i>Xmn</i>I polymorphism was observed in four patients (7.8%), three homozygotes and one heterozygote.</p><p><strong>Conclusions: </strong>Homozygosity for the mild β-globin gene IVS-I-6 allele was the major contributing factor for the TI phenotype among the study subjects. The role of <i>Xmn</i>I SNP and α-thalassemia mutations in ameliorating the TI phenotype was observed in few patients for each factor. The beta - 101 C > T mutation was diagnosed in one patient in homozygote state for the first time in Palestine.</p>","PeriodicalId":37740,"journal":{"name":"BMC Hematology","volume":"19 ","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12878-019-0135-6","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12878-019-0135-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 6

Abstract

Background: We aimed to investigate the molecular basis of β-Thalassemia intermedia (TI) in the West Bank region and its management practices.

Methods: This was a case series multi-center study and included 51 cases of TI. DNA sequencing was used to analyze β-globin gene mutations. Common α-globin gene mutations were screened by Gap-PCR (-α3.7, -α4.2, --MED, αααanti3.7) or DNA sequencing (α2-IVS II 5 nt del). XmnI -158 C > T polymorphisms of Gγ-globin gene was determined by RFLP-PCR.

Results: Seven β-globin gene mutations were observed, namely IVS-I -6 C > T, IVS-I-110 G > A, IVS-II-1 G > A, IVS-I-1 G > A, Codon 37 Trp > Stop, beta - 101 and IVS-II-848 C > A. Ten genotypes were observed. Homozygosity for IVS-I-6 accounted for the majority of TI cases with a frequency of 74.5%. The second common β-globin gene genotype was homozygote IVS-I-110 G > A (5.8%) and homozygote IVS-II-1 G > A (5.8%). The remaining seven genotypes were each detected in about 2% of patients. α-Thalassemia mutations were seen in five patients (9.8%), and included (-α3.7, αααanti3.7 and α2-IVSII-5 nt del). XmnI polymorphism was observed in four patients (7.8%), three homozygotes and one heterozygote.

Conclusions: Homozygosity for the mild β-globin gene IVS-I-6 allele was the major contributing factor for the TI phenotype among the study subjects. The role of XmnI SNP and α-thalassemia mutations in ameliorating the TI phenotype was observed in few patients for each factor. The beta - 101 C > T mutation was diagnosed in one patient in homozygote state for the first time in Palestine.

巴勒斯坦西岸中间型β地中海贫血的分子特征。
背景:我们旨在研究约旦河西岸地区中间型β地中海贫血(TI)的分子基础及其管理实践。方法:本研究为病例系列多中心研究,包括51例TI患者。采用DNA测序方法分析β-珠蛋白基因突变。通过Gap PCR(-α3.7,-α4.2,-MED,αααanti3.7)或DNA测序(α2-IVS II 5 nt del)。XmnI-158 C > 用RFLP-PCR技术检测Gγ-珠蛋白基因的T多态性。结果:观察到7个β-珠蛋白基因突变,即IVS-I-6C > T、 IVS-I-110 G > A、 IVS-II-1 G > A、 IVS-I-1 G > A、 Codon 37 Trp > 停止,测试版- 101和IVS-II-848 C > A.观察到10种基因型。IVS-I-6的纯合性占TI病例的大多数,频率为74.5%。第二个常见的β-珠蛋白基因型是纯合的IVS-I-110 G > A(5.8%)和纯合IVS-II-1 G > A(5.8%)。其余7种基因型分别在约2%的患者中检测到。在5名患者(9.8%)中发现了α-地中海贫血突变,包括(-α3.7、αααanti3.7和α2-IVSII-5 nt del)。在4例(7.8%)患者中观察到XmnI多态性,其中3例为纯合子,1例为杂合子。结论:轻度β-珠蛋白基因IVS-I-6等位基因的纯合性是研究对象TI表型的主要因素。在少数患者中观察到XmnI SNP和α-地中海贫血突变在改善TI表型中的作用。测试版- 101 C > 在巴勒斯坦,一名纯合状态的患者首次被诊断出T突变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Hematology
BMC Hematology Medicine-Hematology
CiteScore
4.10
自引率
0.00%
发文量
0
期刊介绍: BMC Hematology is an open access, peer-reviewed journal that considers articles on basic, experimental and clinical research related to hematology. The journal welcomes submissions on non-malignant and malignant hematological diseases, hemostasis and thrombosis, hematopoiesis, stem cells and transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信